A Phase 3 interventional study of AMG 510 and Docetaxel in KRAS p, G12c Mutated /Advanced Metastatic NSCLC, sponsored by Amgen. Completed at 274 sites in 23 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Phase 3 Study to Compare AMG 510 with Docetaxel in Non Small Cell Lung Cancer (NSCLC) subjects with KRAS p. G12c mutation
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Progression-free Survival (PFS)
PFS was defined as the time from randomization (baseline) until disease progression or death from any cause, whichever occurred first for all participants. Progression was based on blinded independent central review (BICR) of disease response per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). As pre-specified in the statistical analysis plan, for participants who crossed over from docetaxel to AMG 510, the participant's response post first progression or post crossover was not used for the primary analyses. Data are presented per original treatment randomized.
Time frame: Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months
345 participants were enrolled at 148 centers in Europe, North America, Asia, Australia, and South America. The analyses presented in this results summary are based on the primary completion data. The primary completion data cut-off was 02 August 2022. The study is ongoing.
| Milestone | AMG 510 | Docetaxel |
|---|---|---|
| Started | 171 | 174 |
| Switched from docetaxel to amg 510 | 0 | 46 |
| Completed | 0 | 3 |
| Not completed | 171 | 171 |
| Withdrew: Death | 104 | 85 |
| Withdrew: Lost to follow-up | 5 | 2 |
| Withdrew: Withdrawal by subject | 12 | 39 |
| Withdrew: Ongoing in study | 50 | 45 |
PFS was defined as the time from randomization (baseline) until disease progression or death from any cause, whichever occurred first for all participants. Progression was based on blinded independent central review (BICR) of disease response per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). As pre-specified in the statistical analysis plan, for participants who crossed over from docetaxel to AMG 510, the participant's response post first progression or post crossover was not used for the primary analyses. Data are presented per original treatment randomized.
| months | AMG 510 | Docetaxel |
|---|---|---|
| Progression-free Survival (PFS) | 5.62 (4.27 to 7.75) | 4.47 (3.02 to 5.68) |
Collected over Adverse events:for 'Docetaxel' and 'AMG 510', from first dose(FD) to 30 days post last dose, or before FD of AMG 510 if participants cross over, or end of study (EOS) or data cut-off (DCO) which occurred earliest; median[min,max] duration 4.06[0.2,23.7] mons. For 'Docetaxel, then Switched to AMG 510', from FD to EOS/DCO which occurred earliest; median[min,max] duration 7.97[0.8,15.2] mons. Mortality:from randomization until death or DCO; median[min,max] time on study 14.78[0.2,24.3] mons.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Docetaxel | 78/174 (44.8%) | 67/151 (44.4%) | 129/151 (85.4%) |
| AMG 510 | 109/171 (63.7%) | 91/169 (53.8%) | 151/169 (89.3%) |
| Docetaxel, Then Switched to AMG 510 | 17/46 (37%) | 26/46 (56.5%) | 35/46 (76.1%) |
| Event | Docetaxel | AMG 510 | Docetaxel, Then Switched to AMG 510 |
|---|---|---|---|
| Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/151 | 18/169 | 9/46 |
| PneumoniaInfections and infestations | 10/151 | 1/169 | 2/46 |
| Febrile neutropeniaBlood and lymphatic system disorders | 7/151 | 0/169 | 0/46 |
| NauseaGastrointestinal disorders | 1/151 | 2/169 | 2/46 |
| Back painMusculoskeletal and connective tissue disorders | 0/151 | 0/169 | 2/46 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/151 | 2/169 | 2/46 |
| AnaemiaBlood and lymphatic system disorders | 5/151 | 1/169 | 0/46 |
| DiarrhoeaGastrointestinal disorders | 2/151 | 5/169 | 0/46 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 4/151 | 1/169 | 0/46 |
| Angina pectorisCardiac disorders | 0/151 | 0/169 | 1/46 |
| Event | Docetaxel | AMG 510 | Docetaxel, Then Switched to AMG 510 |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 37/151 | 70/169 | 14/46 |
| FatigueGeneral disorders | 43/151 | 27/169 | 6/46 |
| NauseaGastrointestinal disorders | 36/151 | 43/169 | 6/46 |
| AlopeciaSkin and subcutaneous tissue disorders | 35/151 | 3/169 | 0/46 |
| Decreased appetiteMetabolism and nutrition disorders | 29/151 | 39/169 | 5/46 |
| AnaemiaBlood and lymphatic system disorders | 30/151 | 28/169 | 5/46 |
| ConstipationGastrointestinal disorders | 29/151 | 22/169 | 3/46 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 25/151 | 30/169 | 5/46 |
| CoughRespiratory, thoracic and mediastinal disorders | 25/151 | 22/169 | 4/46 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 21/151 | 26/169 | 4/46 |
As pre-specified in the statistical analysis plan, data are presented for all randomized participants according to original treatment assignment, regardless of whether participants switched from receiving docetaxel to receiving AMG 510.
| Age, Continuous(years) | AMG 510 | Docetaxel | Total |
|---|---|---|---|
| Mean | 63.4 ± 9.9 | 63.6 ± 9.1 | 63.5 ± 9.5 |
| Sex: Female, Male(Participants) | AMG 510 | Docetaxel | Total |
|---|---|---|---|
| Female | 62 | 79 | 141 |
| Male | 109 | 95 | 204 |
| Ethnicity (NIH/OMB)(Participants) | AMG 510 | Docetaxel | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 9 | 14 |
| Not Hispanic or Latino | 165 | 163 | 328 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race (NIH/OMB)(Participants) | AMG 510 | Docetaxel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 21 | 22 | 43 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 142 | 144 | 286 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 5 | 8 | 13 |
Showing the first 100 of 274 sites across 23 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Jun 2020 to primary completion in Aug 2022, 25 months.
Results were first posted in May 2023, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotorasib